BR9711809A -
Antigenic or immunogenic polypeptide, processes for treating or preventing a disease or disorder in an individual caused by infection with htlv-i, and with htlv-ii, to elicit in an individual the production of antibodies that specifically bind to htlv- envelope proteins ii and htlv-i, and, to generate an immune response in an individual
- Google Patents
Antigenic or immunogenic polypeptide, processes for treating or preventing a disease or disorder in an individual caused by infection with htlv-i, and with htlv-ii, to elicit in an individual the production of antibodies that specifically bind to htlv- envelope proteins ii and htlv-i, and, to generate an immune response in an individual
Info
Publication number
BR9711809A
BR9711809ABR9711809-5ABR9711809ABR9711809ABR 9711809 ABR9711809 ABR 9711809ABR 9711809 ABR9711809 ABR 9711809ABR 9711809 ABR9711809 ABR 9711809A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ RockefellerfiledCriticalUniv Rockefeller
Priority claimed from PCT/US1997/012776external-prioritypatent/WO1998003197A1/en
Publication of BR9711809ApublicationCriticalpatent/BR9711809A/en
"POLIPEPTìDEO ANTIGêNICO OU IMUNOGêNICO, PROCESSOS PARA TRATAR OU PREVENIR UMA DOENçA OU DISTúRBIO EM UM INDIVìDUO PROVOCADO POR INFECçãO COM HTLV-I, E COM HTLV-II, PARA ELICITAR EM UM INDIVìDUO A PRODUçãO DE ANTICORPOS QUE ESPECIFICAMENTE LIGAM-SE àS PROTEìNAS ENVELOPES HTLV-II E HTLV-I, E, PARA GERAR UMA RESPOSTA IMUNE EM UM INDIVìDUO". A presente invenção refere-se a novos antígenos de proteína derivados de proteína env de HTLV, que são capazes de serem usadas como uma vacina para auxiliar na prevenção e tratamento de infecções por HTLV-I e HTLV-II e novos processos para a produção deste antígeno."ANTIGENIC OR IMMUNOGENIC POLYPEPTIDE, PROCESSES TO TREAT OR PREVENT A DISEASE OR DISORDER IN AN INDIVIDUAL CAUSED BY INFECTION WITH HTLV-I, AND WITH HTLV-II, TO PROVIDE IN A INDIVIDUAL UNDERSTANDING HARMFUL AGRICULTURAL UNIT -II AND HTLV-I, E, TO GENERATE AN IMMUNE RESPONSE IN AN INDIVIDUAL ". The present invention relates to new protein antigens derived from HTLV env protein, which are capable of being used as a vaccine to assist in the prevention and treatment of HTLV-I and HTLV-II infections and new processes for the production of this antigen.
BR9711809-5A1996-07-221997-07-22
Antigenic or immunogenic polypeptide, processes for treating or preventing a disease or disorder in an individual caused by infection with htlv-i, and with htlv-ii, to elicit in an individual the production of antibodies that specifically bind to htlv- envelope proteins ii and htlv-i, and, to generate an immune response in an individual
BR9711809A
(en)
Antigenic or immunogenic polypeptide, processes for treating or preventing a disease or disorder in an individual caused by infection with htlv-i, and with htlv-ii, to elicit in an individual the production of antibodies that specifically bind to htlv- envelope proteins ii and htlv-i, and, to generate an immune response in an individual
Fusion protein Fusion protein The soluble composition of the host cell material Process to generate a neutralizing anti-toxin directed against Clostridium botulinum toxin type A antibody to purify a recombinant fusion protein derived from a Clostridium botulinum toxin type A process to generate an antitoxin neutralizing directed against clostridium difficile toxin type b antibody treatment process process to generate a neutralizing antitoxin directed against clostridium difficile type a toxin composition process to vaccinate an individual to produce neutralizing antitoxin directed against clostridium difficile toxin processing the detection of clostridium antigens difficile in an ample process of purification of toxins from clostridium difficile from a culture and process of generation of a solid dosage form of a bird antitoxin directed against a protein of clostridial toxin
Immunogenic peptide derived from subgroup a or b vrs protein g, nucleic acid sequence, pharmaceutical composition, polyclonal or monoclonal antibodies, diagnostic kit, use of an immunogenic peptide, and, conjugate
Antigenic or immunogenic polypeptide, processes for treating or preventing a disease or disorder in an individual caused by infection with htlv-i, and with htlv-ii, to elicit in an individual the production of antibodies that specifically bind to htlv- envelope proteins ii and htlv-i, and, to generate an immune response in an individual
PROCESS FOR THE PREPARATION OF RECOMBINANT VECTORS AND HBSAG RECOMBINANT HIBRID PARTICLES HAVING THE MORPHOLOGICAL CHARACTERISTICS OF HBSAG ANTIGENIC CONTAINING AN IMMUNOGENIC SEQUENCE THAT INDUCES HIV-DIRECTING NEUTRALIZING ANTIBODIES OR SUSCEPTIVELY OF RECOGNITION BY SUCH ANTIBODIES